Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology

Palumbo, Carlotta; Pecoraro, Angela; Knipper, Sophie; Rosiello, Giuseppe; Luzzago, Stefano; Deuker, Marina; Tian, Zhe; Shariat, Shahrokh F.; Simeone, Claudio; Briganti, Alberto; Saad, Fred; Berruti, Alfredo; Antonelli, Alessandro; Karakiewicz, Pierre I.

doi:10.1016/j.euf.2020.05.003

Cited by 47 publications

(38 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An analysis of worldwide cancer incidence data for the years 1978-2007 indicated a 2:1 male/female case incidence ratio that was constant by age, year and region [5]. The analysis of the Surveillance, Epidemiology, and End Result (SEER) database for the years 2001-2016 show similar rate in males, with age-adjusted incidence rate double that of female in the US [6]. Data from global vital registries revealed a 23.04% increase in age-standardized incidence in kidney cancer between 1990 and 2013 worldwide, which corresponded to a 31.19% increase in males, compared to 8.79% in females [7].…”

Section: Incidencementioning

confidence: 98%

Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence

Peired

Campi

Angelotti

et al. 2021

Cancers

View full text Add to dashboard Cite

Sex and gender disparities have been reported for different types of non-reproductive cancers. Males are two times more likely to develop kidney cancer than females and have a higher death rate. These differences can be explained by looking at genetics and genomics, as well as other risk factors such as hypertension and obesity, lifestyle, and female sex hormones. Examination of the hormonal signaling pathways bring further insights into sex-related differences. Sex and gender-based disparities can be observed at the diagnostic, histological and treatment levels, leading to significant outcome difference. This review summarizes the current knowledge about sex and gender-related differences in the clinical presentation of patients with kidney cancer and the possible biological mechanisms that could explain these observations. Underlying sex-based differences may contribute to the development of sex-specific prognostic and diagnostic tools and the improvement of personalized therapies.

show abstract

Section: Incidencementioning

confidence: 98%

Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence

Peired

Campi

Angelotti

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Prostate cancer (PC) is already the leading cause of cancer among men in the United States and some other Western countries [4]. Additionally, the remaining common malignancies of the urinary system, such as kidney, bladder, and upper urinary tract cancers, also pose a serious threat to human health [5][6][7]. Although surgical techniques and medical therapies (e.g.…”

Section: Introductionmentioning

confidence: 99%

Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis

Chen

et al. 2021

Annals of Medicine

View full text Add to dashboard Cite

Objective: Systemic immune-inflammation index (SII) has been reported in numerous studies to effectively predict the survival outcomes of urinary system cancers; however no agreement has been reached. This meta-analysis aimed to explore the prognostic significance of pre-treatment SII in tumours of the urinary system. Methods: Relevant published articles were selected from Web of Science, PubMed, Embase, and the Cochrane Library up to 30 August 2020. The hazard ratios (HRs) with 95% confidence intervals (CIs) were computed to estimate the associations of pre-treatment SII with overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS) in urinary system cancers. Results: 13 papers were included in our meta-analysis. From the combined data, we found that a high pre-treatment SII indicated a markedly worse OS (

show abstract

“…[4] Meanwhile, the rest of the common malignancies of the urinary system, such as kidney, bladder, and upper urinary tract cancers, also pose a serious threat to human health. [5][6][7] Although surgical techniques and medical therapies (chemotherapy, radiotherapy, immunotherapy and so on) have been rapidly developed in the last ten years, the ve-year survival rate of patients with urinary system cancers is still not optimistic. [8,9] Therefore, especially useful new biomarkers that could be helpful for the diagnosis, evaluation and even improvement of prognosis in urinary system cancers should be identi ed in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Systemic Immune-Inflammation Index is a Promising Noninvasive Biomarker for Predicting the Survival of Urinary System Cancers: A Systematic Review and Meta-Analysis

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: Systemic immune-inflammation index (SII) has been reported in numerous studies to effectively predict the pathological features and survival outcomes of urinary system cancers, but no agreement has been reached. The aim of this meta-analysis is to explore the prognostic significance of pretreatment SII in tumours of the urinary system.Methods: Relevant published articles were selected from Web of Science, PubMed, Embase, and the Cochrane Library up to August 30, 2020. The pooled hazard ratios (HRs), odds ratios (ORs), and standard mean differences (SMDs) with 95% confidence intervals (CIs) were computed to estimate the associations of pretreatment SII with overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS), and clinicopathological parameters in urinary system cancers.Results: Overall, a total of 13 papers published from 2016 to 2020 involving 15 datasets comprising 3974 patients were finally included in our meta-analysis. From the combined data, we found that high SII prior to treatment indicated markedly worse OS (HR =1.98, 95% CI: 1.75–2.23; p < 0.001), PFS (HR: 2.08, 95% CI: 1.32–3.26, p = 0.002) with high heterogeneity (I2 = 80.8%, p < 0.001), and CSS (HR: 2.41, 95% CI: 1.73–3.35, p < 0.001). In addition, patients who have an elevated SII value before receiving treatment might have undesirable pathological characteristics, including large tumour size, poor differentiation grade, and advanced tumour stage (all p < 0.001).Conclusion: Pretreatment SII could be used as a noninvasive and promising biomarker for indicating the prognosis of patients with urinary system cancers.

show abstract

Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology

Cited by 47 publications

References 26 publications

Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence

Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence

Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis

Systemic Immune-Inflammation Index is a Promising Noninvasive Biomarker for Predicting the Survival of Urinary System Cancers: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About